Feminac

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Feminac

Property Description
Active ingredient Cyproterone Acetate, Ethinyl Estradiol
Form Oral tablet (Coated tablet)
Pharmacological class Hormonal Anti-androgen/Estrogen combination
Common use Systemic hormonal regulation
Origin Synthetic steroid hormones

Feminac is a synthetic combination drug classified as a systemic Hormonal Preparation, designed for oral administration. This dual-component medicine belongs to the Anti-androgen/Estrogen combination group, distinguishing it from standard single-hormone therapies. It is widely recognized as a prescription-only medicine (POM) intended to provide targeted hormonal regulation in female patients. Preparations containing Cyproterone Acetate and Ethinyl Estradiol are therapeutic agents for conditions involving androgen excess. The medicine has a role in managing hormone-related physiological challenges.

Composition and Form: Cyproterone and Ethinyl Estradiol

The active core of Feminac is derived from two synthetic steroid hormones: Cyproterone Acetate and Ethinyl Estradiol (EE). This pairing defines the entire preparation, with Cyproterone Acetate providing the crucial anti-androgenic activity and Ethinyl Estradiol contributing the necessary estrogenic support. The medicine is presented as an oral tablet—a solid dosage unit—that is taken for systemic effect throughout the body. The use of synthetic components ensures highly consistent purity and targeted receptor binding profiles for establishing therapeutic efficacy.

General Purpose and Differentiation

The general therapeutic purpose of Feminac is to achieve comprehensive systemic hormonal management by modulating the balance of sex hormones. It is principally engineered to reduce the overall influence of androgens, making it a differentiating choice when addressing physiological processes influenced by excess male hormones. The combination achieves this via two interconnected mechanisms: Androgen Activity Reduction and Hormone Balance Modulation. Combined oral contraceptives provide efficacy in providing cycle control. The consistent, predictable hormonal environment created by this combination defines the foundational utility of this specific class of medicine.

Regulatory References

  1. EMA guidance on Cyproterone/Ethinylestradiol
  2. NIH/NCBI Bookshelf - Oral Contraceptive Pills
  3. NIH

What side effects are possible with Feminac?

Possible Side Effects and Safety Information

The safety profile of this Cyproterone Acetate/Ethinyl Estradiol combination is established based on the regulatory classifications of adverse reactions documented in official sources, categorized by frequency and the organ system affected.

Adverse Reaction Frequencies

Side effects are formally grouped into categories from common to rare, reflecting the incidence documented in clinical use (Source: Regulatory Authorities).

Classification Examples of Documented Reactions
Common Headache, nausea, breast tenderness, abdominal pain, weight changes, mood changes, irregular uterine bleeding.
Uncommon Migraine, fluid retention, decreased libido, rash.
Rare Venous Thromboembolism (VTE), arterial thromboembolism (ATE), liver tumors, hypersensitivity reactions.

Serious Adverse Reactions and Safety Patterns

The regulatory documentation highlights a risk of serious adverse reactions, primarily related to the vascular and hepatic systems. These include potentially life-threatening thromboembolic events such as Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and stroke, which are classified as rare.

Specific safety patterns noted in labeling include:

  • Risk Peak: The highest excess risk of VTE is documented during the first year of use or upon re-starting the medication after an interval of at least one month.
  • Long-Term Exposure: The occurrence of benign liver tumors is primarily associated with prolonged use of hormonal contraceptives.

Safety Constraints and Populations

Regulatory restrictions (contraindications) prohibit the use of this medicine in individuals with pre-existing conditions that increase the risk of serious complications. These constraints include a history of thrombotic disorders, severe hepatic impairment, or known hormone-sensitive malignancies. The risk of serious cardiovascular events is officially noted as significantly increased in women over 35 years of age who smoke.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

This section outlines the officially documented clinical manifestations and required emergency actions for an overdose of products containing Cyproterone Acetate and Ethinyl Estradiol (Feminac), based strictly on government regulatory documents.


Documented Overdose Profile

Overdose with this hormonal combination is generally associated with low acute toxicity, and serious effects are generally not anticipated in adults following the ingestion of large doses, according to regulatory classification. The expected clinical manifestations are typically mild and non-life-threatening.

Documented Manifestation Description
Gastrointestinal Signs Nausea and Vomiting
Endocrine/Genitourinary Withdrawal Bleeding or Vaginal Bleeding

Population Note: Withdrawal bleeding is a documented consideration that may occur in pre-pubertal patients following accidental ingestion.


Emergency Actions and Management

Immediate medical advice must be sought from a doctor or poison control center in the event of suspected ingestion of a high dose. This action is mandated by regulatory authorities. Management of an overdose is symptomatic and supportive, as it is formally documented that no specific antidote is known or available for counteracting the effects of this combination. Treatment focuses solely on supporting the patient and alleviating the clinical manifestations until the drug effects naturally subside.

Therapeutic Uses of Feminac

What Feminac Treats: Main Uses and Benefits

Feminac is commonly used to help with symptomatic relief across therapeutic domains involving physical discomfort. It may assist with managing the overall symptom burden of challenging symptoms, especially in acute and disruptive episodes.

The therapeutic domain of use for this class of medicine is generally relevant for symptoms related to inflammatory or irritative states and localized discomfort, and may be part of symptomatic management for conditions involving episodic or fluctuating manifestations, such as pain associated with acute or episodic changes, fevers, and specific conditions like dysmenorrhoea (menstrual pain) and headache.

“Feminac is applied across domains where additional symptomatic support is needed during phases of increased distress or discomfort.”

Quick Fact: Relevant for Acute Symptom Fluctuations


Easing Acute and Pronounced Symptom Episodes

Feminac is applied across domains where additional symptomatic support is needed, specifically targeting symptoms that become more disruptive during flare-ups and may appear suddenly or intensify over time. This approach offers symptomatic relief that may help patients cope more steadily with symptom fluctuations and supports patients during episodes of heightened discomfort.


Supporting Conditions with Disruptive Manifestations

The medication is commonly used across conditions characterized by periods of heightened symptoms that create noticeable interference with daily functioning. Feminac is relevant in clinical settings marked by heightened patient distress, contributing to easing the overall symptom load and assists with maintaining functional stability when symptoms become momentarily overwhelming.

Regulatory References

  1. Therapeutic Goods Administration (TGA) in Australia

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Feminac?

This information is based on official regulatory labeling for Ibuprofen-containing medicines like Feminac (Ibuprofen Lysine) and dictates eligibility based on patient profile and pre-existing conditions.

Absolute Contraindications (Must Not Use)

Condition/Population Status
History of peptic ulcer, bleeding, or perforation Contraindicated
Severe cardiac, hepatic, or renal failure Contraindicated
Known hypersensitivity to Ibuprofen, Aspirin, or other NSAIDs Contraindicated
Third Trimester of Pregnancy Contraindicated

Eligibility-Related Restrictions

Age: The medicine is not recommended for use in children under 12 years of age or adolescents under 40 kg body weight. Older adults (the elderly) are permitted use but must use the lowest effective dose due to increased risk of serious adverse reactions.

Physiological State: Use during the first and second trimesters of pregnancy requires professional consultation. Use is generally considered acceptable during breastfeeding for short-term use at recommended doses.

Comorbidities: Caution is required and use may be restricted for patients with pre-existing conditions such as mild to moderate kidney/liver impairment, uncontrolled hypertension, or certain gastrointestinal diseases (e.g., Crohn's disease).

What should I know about interactions with other medicines?

Feminac Interactions with other medicines and products

Feminac contains the hormonal components cyproterone acetate and ethinylestradiol, which can interact with several other medicinal products and substance categories, primarily by affecting their concentration in the body.

Key Interaction Classes

The most significant interactions involve drugs that influence the metabolism of the hormonal components, which is primarily mediated by the Cytochrome P450 3A4 (CYP3A4) enzyme system. These interactions may result in changes to the overall efficacy of the medication.

  • Enzyme Inducers: Medicines that induce hepatic enzymes, such as certain anticonvulsants (e.g., phenobarbital, phenytoin, carbamazepine, primidone) and antibiotics (e.g., rifampicin), along with the herbal product St. John's wort, can increase the clearance of cyproterone acetate and ethinylestradiol. This effect can lead to decreased blood concentrations of the active substances and potentially reduce the antiandrogenic and contraceptive reliability of Feminac.
  • Enzyme Inhibitors: Strong inhibitors of CYP3A4 may increase the plasma concentration of the active components, potentially leading to an increase in systemic exposure and associated effects.
  • Antivirals: Certain HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors may either increase or decrease the plasma concentrations of the estrogen and/or progestogen components.
  • Other Drugs: Feminac may also affect the metabolism of co-administered drugs, such as increasing the plasma concentration of ciclosporin or decreasing the concentration of lamotrigine, requiring dose adjustments for the interacting medicine.

Procedural Constraints

Due to its established contraceptive action, Feminac is not to be combined with any other hormonal contraceptive (e.g., other oral pills, patches, or rings). When co-administering with potent enzyme inducers, supplementary non-hormonal barrier contraception is required during co-treatment and for a specified period after discontinuation (e.g., 7 to 28 days, depending on the interacting agent).

Mechanism of Action

Enzyme Inhibition and Mediator Synthesis

Feminac's core molecular action is the inhibition of cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. By reversibly blocking the active sites of these enzymes, the drug prevents the conversion of arachidonic acid into various prostaglandins and related chemical mediators. This interruption in the arachidonic acid cascade defines the drug’s resulting physiological effects.


Modulation of Local Signaling Dynamics

The resulting reduction in prostaglandin concentration alters the activity of peripheral signaling pathways. Feminac's mechanism limits the excitability of local nerve endings and decreases local blood vessel responses by modulating the release of these chemical mediators. This effect modulates the activity of specific physiological responses and results in reduced activation within targeted peripheral systems.


Thermoregulatory Control

A specific consequence of limiting prostaglandin synthesis is the modulation of thermoregulation. Prostaglandins act as key signalers in the hypothalamic center that controls the body's temperature set point. By diminishing the presence of these mediators, the drug engages mechanisms that influence feedback regulation, resulting in the downward adjustment of the body's thermal set point.

Dosage and Administration Information

Instruction Map: How to use Feminac — Administration Guidelines

The following guidelines describe the standardized administration of the Cyproterone Acetate 2 mg / Ethinyl Estradiol 0.035 mg combination.


Administration Scope

Feature Description
Route of administration: Oral
Dosing schedule: One fixed-dose tablet (Cyproterone Acetate 2 mg / Ethinyl Estradiol 0.035 mg) is taken daily in a 21/7 cyclic regimen.
Timing in relation to meals: This medication is taken without regard to meals and is swallowed whole with liquid.
Age-group administration rules: Use is categorized for women of reproductive age.
Missed-dose rules: The protocol for a dose missed by less than 12 hours involves taking the tablet immediately. For a delay of more than 12 hours, the protocol involves discarding the tablet and using a supplementary non-hormonal method for seven days.
Special procedural conditions: Tablet intake occurs at the same time each day, following the specific order indicated on the blister package.

Instruction Classifications (High-Level)

Classification Pattern
Administration method type: Oral
Frequency pattern: Daily for 21 days, followed by a 7-day tablet-free interval (21/7 Cyclic Regimen).
Use-context constraints: The established duration includes discontinuation 3 to 4 cycles after the condition has completely resolved.

Procedural Structure

Step sequence:

  • Take one tablet at the same time daily, following the sequence on the package.
  • Complete 21 consecutive days of active tablets.
  • Initiate a 7-day tablet-free interval.

Connection to the overall use protocol: The use protocol consists of a standardized, fixed-dose, 28-day cyclic administration structure for the oral tablet. Adherence to consistent daily timing and the blister pack sequence are procedural elements of the established schedule. The duration is not for open-ended maintenance, as the protocol includes withdrawal upon the condition's satisfactory resolution.

Recent Clinical Evidence

Research evidence / Overview of Studies for Feminac


Research Evidence for Androgen-Sensitive Acne

Research on this medicine in conditions like moderate to severe acne has been conducted using Randomized Controlled Trials (RCTs) and subsequent Systematic Reviews. These studies are applied in research contexts involving fluctuating or unstable symptoms, and they often compare the medicine against a placebo or against other hormonal or antibiotic treatments. The study populations were mainly women of reproductive age.

Research has explored how symptoms were measured by closely monitoring patients over defined time intervals, typically ranging from six to nine months. Studies report how symptoms evolved in the observed populations by tracking key measurements, such as the total number of acne lesions and calculated scores from standardized severity scales. These scales are relevant in evidence describing how symptoms are measured in a clinical setting. Findings describe patterns observed in the studies related to changes in acne lesion counts and severity scores.


Research Evidence for Moderately Severe Hirsutism

The medicine has also been evaluated in research exploring symptoms of moderately severe hirsutism, which is excessive unwanted hair growth in women. These studies primarily involved RCTs and numerous Systematic Reviews that included populations such as women with Polycystic Ovary Syndrome (PCOS). Research has explored outcomes related to hirsutism by monitoring changes in standardized scores and related biomarkers.

Studies monitored changes in certain hormonal biomarkers such as free and total testosterone. The research structure for hirsutism is often categorized as Moderate due to the variation and limitations observed in some comparative trials. Key limitations include modest sample sizes in some comparison studies and the fact that follow-up durations were limited for capturing very long-term outcomes.


Assessing the Quality and Gaps in the Research

Data for certain groups remain insufficient, and the research does not determine whether an individual will respond similarly to the patterns observed in the study groups. The regulatory and scientific community generally classifies the evidence structure for androgen-sensitive acne as High due to the consistency of findings across many RCTs and systematic reviews. In contrast, the research structure for hirsutism is often categorized as Moderate due to the variation and limitations observed in some comparative trials. Long-term effects are not fully established, particularly concerning the durability of any observed changes after the medicine is stopped.

Frequently Asked Questions (FAQ)

Common questions about Feminac (FAQ)

Q: Is Feminac the same as birth control?

Official documents describe that Feminac possesses a contraceptive action, and official guidance indicates that its combination with other hormonal contraceptives is generally not advised. The medicine is reserved for the treatment of specific androgen-dependent conditions, such as severe acne and hirsutism, and is not designated to be used solely for birth control.

Q: How quickly does Feminac start working?

Official product information indicates that symptomatic relief is usually observed after a minimum of three months of use. Consistent, regular intake of the medication is described as a procedural requirement for following the documented schedule.

Q: Can men use Feminac for any reason?

The medicine is explicitly recommended and indicated for use only in women of childbearing age for the treatment of specific androgen-dependent conditions. The official regulatory scope does not include recommendations for use in men.

Q: What happens if you stop taking Feminac suddenly?

Discontinuation is advised to be determined by the treating physician once the underlying condition has resolved. If the medicine is stopped while relying on its contraceptive effect, supplementary non-hormonal barrier contraception is generally noted as necessary. Sudden cessation of the hormonal components may be associated with a return of the original symptoms.

Q: Can Feminac interact with vitamins or supplements?

According to official warnings, certain herbal products, such as St. John’s wort, are noted to potentially interact with Feminac by reducing the hormone levels in the blood. Official guidance recommends that patients inform their physician of all other medications, supplements, and herbal products being used.

Q: Does Feminac change your menstrual cycle?

Irregular bleeding, such as spotting or breakthrough bleeding, is documented as a potential side effect, particularly as the body adjusts to the medication. An absence of the expected withdrawal bleeding during the tablet-free interval may also occur.

Q: Can Feminac interact with pain relievers like ibuprofen?

The official product label does not specifically detail an interaction with common pain relievers like ibuprofen. However, the regulatory documents contain a general caution that the hormonal components of Feminac may affect the metabolism of other co-administered drugs.

Q: How long can a person safely take Feminac?

Regulatory guidance describes that treatment should be withdrawn three to four cycles after the condition (such as acne or hirsutism) has completely resolved. The official guidance indicates that the need for continued treatment requires routine assessment by the prescribing physician.

Q: Does alcohol consumption affect how Feminac works?

While the specific product information may not detail an alcohol restriction, the hormonal component ethinyl estradiol has been documented in general safety data to have minor interactions with alcohol.

Q: Is it normal to have spotting while on Feminac?

Yes, the occurrence of vaginal bleeding between periods, often referred to as spotting or breakthrough bleeding, is documented in the official safety profile. This is most common during the initial adjustment phase of the first few treatment cycles.

Q: Is Feminac suitable for women over 40?

The medicine is indicated for women of reproductive age. However, official safety documentation notes that the risk of serious cardiovascular events, such as blood clots, is significantly increased in women over 35 years of age who smoke.

Q: Can I take other medications while using Feminac?

Caution is generally described in official documents when combining Feminac with other medicines. The effectiveness of Feminac may be reduced by drugs that speed up liver enzyme activity. Furthermore, its use with any other form of hormonal contraception is contraindicated (strictly forbidden).

Q: What types of allergic reactions are associated with Feminac?

Official regulatory documents list hypersensitivity reactions as a rare adverse reaction associated with the use of the medicine.

Q: What is the purpose of the placebo pills (if applicable) in the Feminac pack?

The 28-day regimen includes a 7-day tablet-free interval, which may include non-active (placebo) tablets. This interval is designed to allow for withdrawal bleeding (which mimics menses) while helping the user maintain the routine of daily tablet intake.

Q: Can Feminac be used by women who have never had children?

The medication is indicated for women of childbearing age. Eligibility is based on the medical condition being treated and is not dependent on whether the patient has previously had children.

Q: What are the reported effects of Feminac on skin health?

The medicine is officially indicated for the treatment of severe androgen-sensitive acne. However, official safety data also notes that the development of chloasma (dark skin patches) or a rash may occur as a side effect.

Q: How often should check-ups occur while taking Feminac?

Official product documentation indicates that the need for continued treatment requires regular assessment by the prescribing physician. Routine medical check-ups are generally noted as a standard part of care for individuals using hormonal treatments.

Q: Are there specific food restrictions while using Feminac?

The product label states that Feminac can be taken without regard to meals. However, certain foods like grapefruit juice may potentially affect how the body processes the hormonal components.

Q: Does Feminac interact with antibiotics?

Yes, official interaction warnings state that certain antibiotics, such as rifampicin, can reduce the blood concentrations of the hormonal components. This effect is due to the antibiotics inducing, or speeding up, liver enzymes.

Q: Is there any research on Feminac and bone density?

Official safety data indicates that the use of high-dose cyproterone acetate alone has been associated with osteoporosis. The estrogen component in Feminac is generally included to counteract this effect and support bone mineral density.

Q: What if I vomit shortly after taking Feminac?

Regulatory documents state that if vomiting or severe diarrhea occurs within 3 to 4 hours after taking the tablet, the absorption of the active components may be incomplete. In this situation, the regulatory guidance directs that the procedure for a missed tablet be followed, which includes the use of supplementary non-hormonal contraception.

Q: Can Feminac be taken by someone with a history of migraines?

Migraine is listed as an Uncommon side effect in official documents. Furthermore, severe or worsening migraine is recognized as a potential warning sign of a serious vascular event, such as a stroke, and is a condition for which immediate medical consultation is advised.

Q: What does 'contraindication' mean for Feminac?

A contraindication is a condition or factor that serves as a reason to withhold a medical treatment due to the potential for harm. For Feminac, official documents indicate that the medicine is contraindicated (must not be used) in the presence of conditions such as a history of blood clots or severe liver impairment.

Q: Can Feminac affect the results of blood tests?

Yes, official regulatory information states that the hormonal components may affect the results of specific blood tests. Official information suggests that patients inform their physician or lab technicians that they are taking the medication if blood work is needed.

Q: Is Feminac affected by grapefruit juice?

Information on the hormonal components suggests that grapefruit juice is known to inhibit a specific liver enzyme (CYP3A4). This action may potentially increase the level of the active ingredients in the blood.

Q: How is Feminac eliminated from the body?

The active components are primarily eliminated from the body as inactive metabolites. The major route of elimination is documented to be through the feces (approximately 70%) and, to a lesser extent, the urine (approximately 30%).

Q: Can Feminac be used during breastfeeding?

Combined hormonal contraceptives are generally described in official guidelines as not being advised during breastfeeding. Official information indicates they may reduce the quantity and quality of breast milk, and small amounts of the hormones are known to be excreted into the milk.

Q: Is Feminac safe for teenagers to use?

The medication is indicated for women of childbearing age, which includes adolescents whose menstrual cycles are already established. Use is based on the medical need to treat androgen-sensitive conditions.

Q: Does Feminac affect cholesterol levels?

Studies indicate that the combination of hormones in Feminac may lead to changes, such as increases, in triglycerides, total cholesterol, and HDL cholesterol. Product information describes that the monitoring of these lipid profiles is recommended by health authorities.

How should Feminac be stored and disposed of?

How to Store and Dispose of Feminac?

The storage and disposal of Feminac (Cyproterone Acetate/Ethinyl Estradiol tablets) must adhere strictly to official regulatory requirements to ensure product integrity and safety.


Storage Requirements

Feminac must be stored out of the sight and reach of children.

Storage Condition Requirement
Temperature Do not store above 30 C.
Protection Store in the original package to protect from light and moisture.

Disposal Instructions

Unused or expired Feminac must not be thrown away via wastewater or household waste.

Disposal of any unused product or waste material must be carried out in accordance with local requirements. Patients are advised to consult their pharmacist for appropriate pharmaceutical waste disposal procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Feminac found in:

A-Z Index: